8-K/A filing — Intellia Therapeutics, Inc. (NTLA)
Filed: 2026-11-13 AccNo: 0001193125-26-460948 Size: 29 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Intellia Therapeutics released its financial results and business updates for the third quarter of 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0001193125-26-460948 Size: 29 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Intellia Therapeutics announced new clinical and patient-reported data for its CRISPR-based therapy, lonvoguran ziclumeran (lonvo-z), demonstrating significant reductions in hereditary angioedema attack rates.
Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.
J.P. Morgan analyst Brian Cheng maintained a 'Sell' rating on Intellia Therapeutics while raising the price target from $8 to $9.
Intellia Therapeutics announced that it will participate in the upcoming Jefferies Global Healthcare Conference in London.
Intellia Therapeutics awarded equity-based inducement grants to three new employees as a material inducement to employment.